{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Tackling \u201cthe Biggest Question That Everyone Is Asking\u201d in Breast Cancer Care","description":"How are oncologists currently approaching the care of patients with ESR1-mutated advanced breast cancer in practice?  Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, speaks with  Wassim Mchayleh, MD, MBA, the clinical program director of the breast cancer program at AdventHealth Cancer Institute and associate professor of medicine at the University of Central Florida in Orlando, about how to best use oral selective estrogen receptor degraders. \u201cAnd the big question is \u2018Can we use SERDs in combination, or are SERDs effective in patients without an ESR1 mutation?\u2019 Can we go outside the current approved guidelines? And I think that\u2019s the biggest question that everyone is asking today,\u201d notes Dr. Mchayleh. Dr. Cobain&amp;nbsp;and Dr. Mchayleh reported various disclosures. ","author_name":"Oncology News Central Peer-Spectives","author_url":"https:\/\/www.oncologynewscentral.com\/podcasts\/peer-spectives","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40560480\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/3662d7\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/40560480"}